ClinicalTrials.gg
Active, not recruitingNCT03089905TREXUpdated Nov 12, 2026

A Study to Compare the Long-term Outcomes After Two Different Anaesthetics

A Phase 3 interventional study of Sevoflurane and Remifentanil in Anesthesia, Neurotoxicity and Child Development, sponsored by Murdoch Childrens Research Institute. Active, not recruiting at 21 sites in 4 countries. Open to participants aged Up to 2 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Murdoch Childrens Research Institute · Phase 3, Interventional, and Treatment

How we know

Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
Up to 2 Years
Sex
All
01

Study summary

There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios.

The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha 2 agonists (such as dexmedetomidine).

Some, but not all, human cohort studies show an association between exposure to anaesthesia in infancy or early childhood and later changes in cognitive tests, school performance or risk of developing neurodevelopmental disorders. The evidence is weak due to possible confounding.

A recent well designed cohort study (the PANDA study) comparing young children that had hernia repair to their siblings found no evidence for a difference in a range of detailed neuropsychological tests. In that study most children were exposed to up to two hours of anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under regional or general anesthesia and has found no evidence for a difference in neurodevelopment when tested at two years of age. The GAS and PANDA studies confirm the animal data that short exposure is unlikely to cause any neurodevelopmental impact.

The impact of longer exposures is still unknown. In humans the strongest evidence for an association between surgery and poor neurodevelopmental outcome is in infants having major surgery. However, this is also the group where confounding is most likely.

The aim of our study is to see if a new combination of anaesthetic drugs results in a better long-term developmental outcome than the current standard of care for children having anaesthesia expected to last 2 hours or longer.

Children will be randomised to receive either a low dose sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic.

They will receive a neurodevelopmental assessment at 3 years of age to assess global cognitive function.

02

Conditions studied

  • Anesthesia
  • Neurotoxicity
  • Child Development
03

In context

Neurotoxicity Syndromes

133 studies on the registry are indexed under Neurotoxicity Syndromes; 17 are open to participants now.

This study's enrollment of 450 is above the median of 92 across 86 interventional studies indexed under Neurotoxicity Syndromes.

Browse Neurotoxicity Syndromes studies →

Lead sponsor

Murdoch Childrens Research Institute is the lead sponsor of 99 studies on the registry; 34 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Younger than 2 years (chronological age)
  • Scheduled for anaesthesia that is expected to last at least 2 hours (and/or total operating room time is scheduled to be at least 2.5 hours)
  • Has a legally acceptable representative capable of understanding the document and providing consent on the participant's behalf.

Exclusion criteria

Exclusion Criteria:

  • Known neurologic, chromosomal or congenital anomaly which is likely to be associated with poor neurobehavioural outcome
  • Existing diagnosis of behavioural or neurodevelopmental disability
  • Prematurity (defined as \< 36 weeks gestational age at birth)
  • Birth weight less than 2 kg.
  • Congenital cardiac disease requiring surgery
  • Intracranial neurosurgery and intracranial craniofacial surgery (isolated cleft lip is not an exclusion)
  • Previous cumulative exposure to general anaesthesia exceeding 2 hours
  • Planned future cumulative exposure to anaesthesia exceeding 2 hours before the age of 3 years.
  • Any specific to any aspect of the protocol
  • Previous adverse reaction to any anaesthetic
  • Circumstances likely to make long term follow-up impossible
  • Living in a household where the primary language spoken at home is not a language in which we can administer the Wechsler Preschool and Primary School Intelligence Scale
  • Planned postoperative sedation with any agent except opioids (e.g. benzodiazepines, dexmedetomidine, ketamine, barbiturates, propofol, clonidine, chloral hydrate, and other non-opioid sedatives). For example if such sedation is planned for post-operative ventilation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
450 participants (actual)

Study arms

  • Experimental
    Sevoflurane/dexmedetomidine/remifentanil

    Dexmedetomidine: loading dose of 1mcg/kg over 10 minutes followed by an infusion of at 1 mcg/kg/hr. Remifentanil: loading dose 1 mcg/kg over 2 minutes followed by an infusion starting at 0.1 mcg/kg/min or greater. Sevoflurane: end tidal concentration of 0.6 -0.8% or less.

    Drug: Sevoflurane · Drug: Remifentanil · Drug: Dexmedetomidine

  • Active comparator
    Sevoflurane

    End tidal concentration of 2.5-3.0% or greater.

    Drug: Sevoflurane

Interventions

  • Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.

    Also known as: Sevorane

  • Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.

    Also known as: Ultiva

  • Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.

    Also known as: Precedex, Dexmedetomidine Ever Pharma

06

What researchers measure

Primary outcomes

  1. Full Scale IQ

    Global cognitive function as assessed by the full scale IQ score of the Wechsler Preschool and Primary School Intelligence Scale.

    Time frame: 3 years of age

Secondary outcomes

  1. incidence of intra-operative hypotension

    Blood pressure measurements will be recorded during surgery

    Time frame: 150 minutes- duration of surgery (baseline)

  2. incidence of intra-operative bradycardia

    Heart rate will be recorded during surgery

    Time frame: 150 minutes- duration of surgery (baseline)

  3. Post-operative pain

    Pain scores will be recorded after surgery

    Time frame: 60 minutes- after surgery

  4. Time to recovery

    Time of removal of airway, eye-opening and discharge from PACU will be recorded.

    Time frame: 60 minutes- after surgery

  5. Language outcomes

    Clinical Evaluation of Language Fundamentals- Preschool, Version 2 (CELF-P2)

    Time frame: 3 years of age

  6. Attention/Executive Function/impulse control

    A Developmental NEuroPSYchological Assessment- Second Edition (NEPSY-2): Statue Subtest

    Time frame: 3 years of age

  7. Memory

    A Developmental NEuroPSYchological Assessment- Second Edition (NEPSY-2): Narrative memory

    Time frame: 3 years of age

  8. Adaptive behaviour

    Adaptive Behavior Assessment System - Third Edition (ABAS-III)

    Time frame: 3 years of age

  9. Clinical Behavior

    Child Behavior Checklist (CBCL)

    Time frame: 3 years of age

  10. Executive Function

    Behavior Rating of Executive Function- Preschool (BRIEF-P)

    Time frame: 3 years of age

  11. Social Skills

    Social Skills Improvement System (SSIS)

    Time frame: 3 years of age

07

Study locations

21 sites
08

References and documents

Publications

  • Saynhalath R, Disma N, Taverner FJ, von Ungern-Sternberg BS, Andropoulos D, Ng AS, Shields BB, Izzo F, Lee-Archer P, McCann ME, Montagnini L, Kuppers B, Lenares E, Sheppard S, de Graaff JC, Lee KJ, Wang X, Szmuk P, Davidson AJ, Skowno JJ; TREX (Trial Remifentanil DEXmedetomidine) Consortium. Short-term Outcomes in Infants after General Anesthesia with Low-dose Sevoflurane/Dexmedetomidine/Remifentanil versus Standard-dose Sevoflurane (the TREX Trial). Anesthesiology. 2024 Dec 1;141(6):1075-1085. doi: 10.1097/ALN.0000000000005232. PubMed 39283983 ↗
  • Oltean T, Ostlund S, Rinehart J, Vandenabeele P, Kain ZN, Coeckelenbergh S. Neuronal Cell Death Modalities and Protective Mechanisms Induced By Sevoflurane: A Narrative Review. Anesth Analg. 2026 Oct 1;143(4):807-821. doi: 10.1213/ANE.0000000000008035. Epub 2026 May 6. PubMed 42090240 ↗
  • Chen DX, Tan ZM, Lin XM. General Anesthesia Exposure in Infancy and Childhood: A 10-year Bibliometric Analysis. J Perianesth Nurs. 2024 Oct;39(5):772-781. doi: 10.1016/j.jopan.2023.12.006. Epub 2024 Mar 21. PubMed 38520467 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The de-identified data set collected for this analysis of the TREX trial will be available six months after publication of the primary outcome. The study protocol, analysis plan and consent forms will also be available. The data may be obtained from the Murdoch Children's Research Institute by emailing andrew.davidson@rch.org.au.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 6 months after publication of primary outcome

Access criteria: Prior to releasing any data the following are required: a data access agreement must be signed between relevant parties, the TREX Trial Steering Committee must see and approve the analysis plan describing how the data will be analysed, there must be an agreement around appropriate acknowledgement and any additional costs involved must be covered. Data will only be shared with a recognised research institution which has approved the proposed analysis plan.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2017 (actual). Primary completion is estimated for Dec 2026, 112 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2017
First posted
Mar 24, 2017
StartActual
Aug 10, 2017
Primary completionEst.
Dec 2026was Oct 2026
CompletionEst.
Dec 2026was Oct 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Dec 2026
Nov 12, 2026
Study completion
Oct 2026→Dec 2026
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Oct 2026→Dec 2026
    Study completion Oct 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03089905
Lead sponsor
Murdoch Childrens Research Institute
Collaborators
Sydney Children's Hospitals Network, Baylor College of Medicine, Boston Children's Hospital, The Cleveland Clinic, University of Texas, Southwestern Medical Center at Dallas, Royal Children's Hospital, Children's Hospital of Philadelphia, Queensland Children's Hospital, Perth Children's Hospital, Women and Children's Hospital, Istituto Giannina Gaslini, Flinders Medical Centre
Responsible party
Sponsor
First posted
Mar 24, 2017
Start date
Aug 10, 2017
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Andrew J Davidson, MD
study chair · Royal Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Remifentanil · Dexmedetomidine

Start the discussion